Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free SUPN Stock Alerts

Supernus Pharmaceuticals (SUPN) Financials

Supernus Pharmaceuticals logo
$48.27 +1.12 (+2.38%)
As of 08/14/2026 04:00 PM Eastern
Compare
Annual Income Statements for Supernus Pharmaceuticals

Annual Income Statements for Supernus Pharmaceuticals

This table shows Supernus Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 14 511 57 111 113 127 53 61 1.32 74 -39
Consolidated Net Income / (Loss)		 14 91 57 111 113 127 53 61 1.32 74 -39
Net Income / (Loss) Continuing Operations		 14 511 57 111 113 127 53 61 1.32 74 -39
Total Pre-Tax Income 		15 50 101 140 147 169 73 61 2.77 98 -49
Total Operating Income		 21 54 100 144 149 174 86 46 -5.27 82 -62
Total Gross Profit		 139 413 287 394 376 468 505 580 524 584 644
Total Revenue		 147 425 302 409 393 520 580 667 608 662 719
Operating Revenue		 147 425 302 409 393 520 580 667 608 662 719
Total Cost of Revenue		 8.42 12 15 15 17 52 75 87 84 78 75
Operating Cost of Revenue		 8.42 12 15 15 17 52 75 87 84 78 75
Total Operating Expenses		 118 -61 187 249 228 294 419 534 529 502 707
Selling, General & Admin Expense		 89 106 138 155 153 201 305 377 336 322 486
Research & Development Expense		 29 43 50 89 69 76 90 75 92 109 106
Amortization Expense		 - - - 5.19 5.18 16 30 83 82 78 89
Impairment Charge		 - - - - - - - 0.00 20 0.00 0.00
Other Special Charges / (Income)		 - - - 0.00 0.00 1.90 -6.53 -0.51 -1.52 -6.11 25
Total Other Income / (Expense), net		 -6.23 -3.85 1.08 -4.27 -1.08 -5.05 -13 15 8.04 16 13
Interest Expense		 7.11 5.76 - - - - - 7.07 2.42 0.00 0.00
Other Income / (Expense), net		 0.19 0.45 1.08 -4.27 -1.08 -5.05 -13 22 10 16 13
Income Tax Expense		 0.67 -41 43 29 34 42 20 0.03 1.45 24 -10
Basic Earnings per Share		 $0.29 $1.84 $1.13 $2.13 $2.16 $2.41 $1.01 $1.13 $0.02 $1.34 ($0.68)
Weighted Average Basic Shares Outstanding		 47.49M 49.47M 50.76M 51.99M 52.41M 52.62M 53.10M 53.67M 54.54M 55.10M 56.45M
Diluted Earnings per Share		 $0.28 $1.76 $1.08 $2.05 $2.10 $2.36 $0.98 $1.04 $0.02 $1.32 ($0.68)
Weighted Average Diluted Shares Outstanding		 51.16M 51.71M 53.30M 54.10M 53.82M 53.69M 54.36M 61.68M 55.51M 55.96M 56.45M
Weighted Average Basic & Diluted Shares Outstanding		 48.10M 49.60M 51.54M 52.32M 52.53M 52.92M 53.39M 54.38M - 55.81M 57.58M

Quarterly Income Statements for Supernus Pharmaceuticals

This table shows Supernus Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29 -58
Consolidated Net Income / (Loss)		 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29 -58
Net Income / (Loss) Continuing Operations		 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29 -58
Total Pre-Tax Income 		0.99 0.24 26 45 26 -5.83 17 -58 -1.91 -5.95 -58
Total Operating Income		 -1.00 -3.15 23 41 21 -10 12 -60 -3.94 -8.33 -58
Total Gross Profit		 145 127 150 158 148 134 149 173 189 184 185
Total Revenue		 164 144 168 176 174 150 165 192 212 208 219
Operating Revenue		 164 144 168 176 174 150 165 192 212 208 219
Total Cost of Revenue		 20 16 18 18 26 16 17 19 23 23 34
Operating Cost of Revenue		 20 16 18 18 26 16 17 19 23 23 34
Total Operating Expenses		 146 130 128 117 127 144 136 233 193 193 243
Selling, General & Admin Expense		 81 87 86 70 79 90 94 180 122 125 134
Research & Development Expense		 23 25 26 29 29 27 22 29 28 39 29
Amortization Expense		 21 20 20 19 18 20 21 24 25 26 25
Impairment Charge		 - - - - - - 0.00 - - - 55
Other Special Charges / (Income)		 -0.20 -1.10 -4.36 -1.02 0.36 7.66 0.00 0.00 18 2.39 0.00
Total Other Income / (Expense), net		 1.99 3.40 3.73 4.10 4.98 4.43 4.53 2.28 2.02 2.38 0.63
Interest Expense		 - - - - - - 0.00 - - - 2.32
Interest & Investment Income		 - - - - - - 4.53 - - - 2.63
Other Income / (Expense), net		 1.99 3.40 3.73 4.10 4.98 4.43 - 2.28 2.02 2.38 0.32
Income Tax Expense		 -0.19 0.12 6.39 6.45 11 6.00 -5.83 -13 2.19 -3.66 0.72
Basic Earnings per Share		 $0.02 $0.00 $0.36 $0.70 $0.28 ($0.21) $0.40 ($0.80) ($0.07) ($0.04) ($1.01)
Weighted Average Basic Shares Outstanding		 54.54M 54.80M 54.98M 55.15M 55.10M 55.86M 56.02M 56.55M 56.45M 57.65M 58.07M
Diluted Earnings per Share		 $0.04 $0.00 $0.36 $0.69 $0.27 ($0.21) $0.40 ($0.80) ($0.07) ($0.04) ($1.01)
Weighted Average Diluted Shares Outstanding		 55.51M 55.63M 55.72M 56.02M 55.96M 55.86M 56.64M 56.55M 56.45M 57.65M 58.07M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 54.97M 55.11M 55.22M 55.81M 55.99M 56.07M 57.34M 57.58M 58.04M 58.13M

Annual Cash Flow Statements for Supernus Pharmaceuticals

This table details how cash moves in and out of Supernus Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.90 -58 34 92 -11 107 -85 -110 -18 -5.72 61
Net Cash From Operating Activities		 35 67 115 129 143 138 127 117 111 172 47
Net Cash From Continuing Operating Activities		 35 -24 115 129 143 138 127 117 111 172 47
Net Income / (Loss) Continuing Operations		 14 0.00 57 111 113 127 53 61 1.32 74 -39
Consolidated Net Income / (Loss)		 14 - 57 111 113 127 53 61 1.32 74 -39
Depreciation Expense		 0.92 2.40 8.13 7.06 6.66 18 33 86 85 80 92
Amortization Expense		 0.75 0.52 -0.51 10 12 14 18 5.35 0.41 1.82 -1.53
Non-Cash Adjustments To Reconcile Net Income		 25 22 31 48 17 14 31 16 61 59 40
Changes in Operating Assets and Liabilities, net		 -6.35 -49 18 -48 -5.03 -34 -7.95 -51 -36 -43 -45
Net Cash From Investing Activities		 -39 -36 -86 -413 -158 -35 -82 -217 269 -190 4.11
Net Cash From Continuing Investing Activities		 -39 -36 -86 -413 -158 -35 -82 -217 269 -190 4.11
Purchase of Property, Plant & Equipment		 -2.10 -1.60 -2.03 -0.84 -1.39 -3.69 -2.05 -0.41 -0.55 -0.73 -1.34
Acquisitions		 -11 -19 -11 0.00 0.00 -299 -312 - 0.00 0.00 -293
Purchase of Investments		 -64 -47 -102 -492 -410 -96 -312 -407 -102 -688 -476
Sale and/or Maturity of Investments		 38 32 29 80 253 378 531 191 371 499 774
Net Cash From Financing Activities		 1.87 2.05 5.68 376 3.93 3.56 -130 -10 -398 12 9.13
Net Cash From Continuing Financing Activities		 1.87 2.05 5.68 376 3.93 3.56 -130 -10 -398 12 9.13
Repayment of Debt		 - - - - 0.00 0.00 -138 0.00 -496 0.00 0.00
Issuance of Debt		 - - 0.00 403 - - - 0.00 93 0.00 0.00
Issuance of Common Equity		 1.87 2.05 5.68 77 3.93 4.36 7.10 12 6.61 15 38
Other Financing Activities, net		 - - 0.00 -93 0.00 -0.80 0.80 -23 -1.99 -2.72 -28
Cash Interest Paid		 0.83 0.49 0.13 1.34 2.52 2.52 2.52 2.52 1.95 0.00 0.00
Cash Income Taxes Paid		 - - 1.59 35 52 45 25 16 37 53 16

Quarterly Cash Flow Statements for Supernus Pharmaceuticals

This table details how cash moves in and out of Supernus Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -20 -12 -11 -20 38 47 29 8.11 -23 56 -4.92
Net Cash From Operating Activities		 45 38 36 54 44 31 59 -62 20 67 -4.81
Net Cash From Continuing Operating Activities		 45 38 36 54 44 31 59 -62 20 67 -4.81
Net Income / (Loss) Continuing Operations		 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29 -58
Consolidated Net Income / (Loss)		 1.18 0.12 20 38 15 -12 22 -45 -4.11 -2.29 -58
Depreciation Expense		 22 21 21 20 19 20 21 25 25 26 26
Amortization Expense		 0.73 1.89 -0.36 0.97 -0.67 -1.07 -0.03 -0.92 0.50 -0.19 -0.34
Non-Cash Adjustments To Reconcile Net Income		 30 21 11 24 15 6.97 5.48 11 13 13 48
Changes in Operating Assets and Liabilities, net		 -8.69 -5.66 -15 -30 -4.43 16 9.23 -52 -15 30 -20
Net Cash From Investing Activities		 -66 -52 -49 -77 -13 37 -31 49 -51 -19 7.09
Net Cash From Continuing Investing Activities		 -66 -52 -49 -77 -13 37 -31 49 -51 -19 7.09
Purchase of Property, Plant & Equipment		 0.04 -0.25 -0.06 -0.20 -0.21 -0.33 -0.46 -0.13 -0.43 0.00 -0.57
Purchase of Investments		 -102 -194 -124 -225 -145 -119 -141 -127 -90 -78 -50
Sale and/or Maturity of Investments		 36 142 75 148 133 156 110 469 39 59 58
Net Cash From Financing Activities		 1.09 1.57 1.66 3.08 5.89 -21 0.94 21 8.53 9.12 -7.20
Net Cash From Continuing Financing Activities		 1.09 1.57 1.66 3.08 5.89 -21 0.94 21 8.53 9.12 -7.20
Issuance of Common Equity		 1.09 2.91 1.66 3.46 6.88 2.04 3.28 24 8.56 14 4.12
Other Financing Activities, net		 - -1.34 -0.00 -0.39 -0.99 -23 -2.34 -2.67 -0.03 -4.56 -11
Cash Income Taxes Paid		 9.55 0.34 20 20 13 0.27 12 3.08 0.27 -0.41 0.87

Annual Balance Sheets for Supernus Pharmaceuticals

This table presents Supernus Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 189 310 424 978 1,160 1,504 1,689 1,703 1,278 1,368 1,453
Total Current Assets		 106 151 228 493 473 630 602 734 493 686 644
Cash & Equivalents		 33 66 100 192 181 289 203 93 75 69 128
Short-Term Investments		 29 24 40 164 166 134 136 368 180 384 180
Accounts Receivable		 26 42 66 103 87 141 149 165 144 142 188
Inventories, net		 13 17 16 26 27 48 86 92 77 54 82
Prepaid Expenses		 5.26 2.96 6.52 8.89 12 19 27 16 17 36 65
Plant, Property, & Equipment, net		 3.87 4.34 5.12 4.10 17 0.00 0.00 15 14 12 11
Total Noncurrent Assets		 79 154 191 480 671 874 1,088 953 771 670 798
Goodwill		 - - - - 0.00 78 118 117 117 117 125
Intangible Assets		 0.98 36 36 31 25 364 785 702 600 522 569
Noncurrent Deferred & Refundable Income Taxes		 - 42 21 30 32 - - - - 0.00 38
Other Noncurrent Operating Assets		 23 0.33 0.39 0.38 22 81 66 40 38 32 65
Total Liabilities & Shareholders' Equity		 189 310 424 978 1,160 1,504 1,689 1,703 1,278 1,368 1,453
Total Liabilities		 101 118 157 525 565 759 873 816 356 332 391
Total Current Liabilities		 57 81 123 161 161 245 315 688 290 292 338
Short-Term Debt		 - - - - 0.00 31 45 423 52 47 31
Accounts Payable		 4.31 8.06 6.84 40 50 79 118 96 80 76 108
Accrued Expenses		 52 69 96 107 108 126 133 152 154 169 161
Other Current Liabilities		 0.50 3.10 4.28 2.18 3.24 9.08 20 17 4.28 0.00 38
Total Noncurrent Liabilities		 44 37 34 363 404 514 558 128 66 40 53
Other Noncurrent Operating Liabilities		 35 31 33 34 59 89 52 79 41 35 53
Commitments & Contingencies		 - - - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 88 192 267 453 595 745 816 886 922 1,036 1,062
Total Preferred & Common Equity		 88 192 267 453 595 745 816 886 922 1,036 1,062
Total Common Equity		 88 192 267 453 595 745 816 886 922 1,036 1,062
Common Stock		 264 276 295 370 388 409 434 408 440 479 544
Retained Earnings		 -176 -84 -27 86 200 326 380 481 483 556 518
Accumulated Other Comprehensive Income / (Loss)		 -0.49 -0.13 -0.75 -3.16 7.42 8.98 1.54 -3.21 -0.59 -0.19 -0.04

Quarterly Balance Sheets for Supernus Pharmaceuticals

This table presents Supernus Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 1,792 1,293 1,285 1,304 1,316 1,343 1,347 1,382 1,420 1,501 1,428
Total Current Assets		 883 424 449 544 591 640 688 739 594 732 723
Cash & Equivalents		 58 25 95 63 52 32 116 145 151 185 180
Short-Term Investments		 170 127 105 234 295 372 348 378 130 199 192
Accounts Receivable		 144 137 142 148 152 145 146 141 171 182 212
Inventories, net		 91 91 83 75 68 64 49 44 79 87 84
Prepaid Expenses		 16 45 24 24 23 27 29 31 62 78 56
Plant, Property, & Equipment, net		 15 14 14 13 12 12 11 11 11 10 10
Total Noncurrent Assets		 894 855 822 747 713 691 648 632 815 759 694
Goodwill		 117 117 117 117 117 117 117 117 119 121 119
Intangible Assets		 682 662 641 580 560 540 502 481 623 550 469
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - 6.18 8.79 31 49
Other Noncurrent Operating Assets		 40 38 39 38 36 34 29 28 64 58 56
Total Liabilities & Shareholders' Equity		 1,792 1,293 1,285 1,304 1,316 1,343 1,347 1,382 1,420 1,501 1,428
Total Liabilities		 880 373 373 375 358 336 317 319 370 424 397
Total Current Liabilities		 732 253 288 315 309 292 282 286 331 374 347
Short-Term Debt		 481 21 46 51 47 47 30 0.00 11 0.00 0.00
Accounts Payable		 95 83 78 86 83 76 77 78 109 101 108
Accrued Expenses		 148 149 162 167 175 169 170 181 184 190 199
Other Current Liabilities		 7.49 0.00 0.71 9.55 3.62 0.00 4.75 28 26 83 40
Total Noncurrent Liabilities		 148 121 85 60 50 44 35 32 39 50 50
Other Noncurrent Operating Liabilities		 98 76 50 41 38 37 34 32 39 50 50
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 912 920 912 929 957 1,007 1,031 1,064 1,050 1,077 1,031
Total Preferred & Common Equity		 912 920 912 929 957 1,007 1,031 1,064 1,050 1,077 1,031
Total Common Equity		 912 920 912 929 957 1,007 1,031 1,064 1,050 1,077 1,031
Common Stock		 416 424 432 447 455 466 486 497 528 561 574
Retained Earnings		 498 497 481 483 503 541 545 567 522 516 457
Accumulated Other Comprehensive Income / (Loss)		 -2.33 -1.78 -1.21 -0.53 -0.37 0.08 -0.16 -0.20 -0.07 -0.26 -0.14

Annual Metrics And Ratios for Supernus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Supernus Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 57,339,350.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 57,339,350.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.67
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 20 98 57 114 114 131 63 46 -2.50 62 -44
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 3.52% -0.26% 5.69% -3.99%
Earnings before Interest and Taxes (EBIT)		 21 55 101 140 147 169 73 68 5.18 98 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 23 58 108 157 166 200 124 159 90 180 41
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 15 46 93 101 120 -261 -366 114 49 134 -198
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -22 30 -6.20 7.67 1.75 393 822 754 702 629 784
Increase / (Decrease) in Invested Capital		 5.12 52 -37 14 -5.92 391 429 -68 -52 -73 155
Book Value per Share		 $1.80 $3.87 $5.22 $8.67 $11.35 $14.14 $15.34 $16.39 $16.87 $18.76 $18.52
Tangible Book Value per Share		 $1.78 $3.14 $4.52 $8.07 $10.88 $5.74 ($1.62) $1.23 $3.75 $7.19 $6.41
Total Capital		 95 196 267 782 941 1,166 1,281 1,309 974 1,083 1,093
Total Debt		 7.09 4.17 0.00 329 345 421 465 423 52 47 31
Total Long-Term Debt		 7.09 4.17 0.00 329 345 390 421 0.00 0.00 0.00 0.00
Net Debt		 -110 -161 -274 -445 -594 -352 6.54 -132 -219 -406 -278
Capital Expenditures (CapEx)		 2.10 1.60 2.03 0.84 1.39 3.69 2.05 0.41 0.55 0.73 1.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -19 -35 -24 -35 -6.32 -8.63 7.95 0.11 -13 28
Debt-free Net Working Capital (DFNWC)		 49 71 105 332 312 416 331 469 255 441 337
Net Working Capital (NWC)		 49 71 105 332 312 385 286 46 203 394 306
Net Nonoperating Expense (NNE)		 5.95 6.97 -0.61 3.38 0.83 3.80 9.38 -15 -3.82 -12 -5.05
Net Nonoperating Obligations (NNO)		 -110 -161 -274 -445 -594 -352 6.54 -132 -219 -406 -278
Total Depreciation and Amortization (D&A)		 1.67 2.92 7.62 17 18 32 51 91 85 82 90
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.30 $1.84 $1.13 $2.13 $2.16 $2.41 $1.01 $1.13 $0.00 $1.34 ($0.68)
Adjusted Weighted Average Basic Shares Outstanding		 47.49M 49.47M 50.76M 51.99M 52.41M 52.62M 53.10M 53.67M 0.00 55.10M 56.45M
Adjusted Diluted Earnings per Share		 $0.28 $1.76 $1.08 $2.05 $2.10 $2.36 $0.98 $1.04 $0.00 $1.32 ($0.68)
Adjusted Weighted Average Diluted Shares Outstanding		 51.16M 51.71M 53.30M 54.10M 53.82M 53.69M 54.36M 61.68M 0.00 55.96M 56.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $2.16 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.40M 50.16M 51.54M 52.32M 52.53M 52.92M 53.39M 54.38M 0.00 55.81M 57.58M
Normalized Net Operating Profit after Tax (NOPAT)		 20 38 57 114 114 132 58 46 9.38 57 -26
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Supernus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Supernus Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 57,339,350.00 57,581,712.00 58,039,721.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 57,339,350.00 57,581,712.00 58,039,721.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.07 -0.04 -1.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -1.80% -6.58% 24.17% 14.17% 5.99% 4.30% -1.71% 9.34% - 38.63% 32.40%
EBITDA Growth		 -59.76% -25.21% 904.02% 107.49% 90.45% -41.11% -18.57% -151.61% - 48.32% -196.34%
EBIT Growth		 -97.30% -97.69% 262.19% 354.47% 2,564.85% -2,499.59% -36.62% -228.95% - -2.04% -574.82%
NOPAT Growth		 -104.75% -116.54% 238.81% 366.12% 1,152.04% -346.21% -4.11% -220.51% - 18.76% -347.59%
Net Income Growth		 -95.39% -99.27% 2,496.63% 340.97% 1,204.51% -9,637.90% 12.97% -217.20% - 80.61% -359.44%
EPS Growth		 -90.91% -100.00% 1,900.00% 337.93% 575.00% 0.00% 11.11% -215.94% - 80.95% -352.50%
Operating Cash Flow Growth		 63.10% -21.83% 288.75% 49.18% -1.23% -20.32% 64.31% -215.22% - 117.41% -108.22%
Free Cash Flow Firm Growth		 -45.53% -76.11% 530.11% 264.09% 67.51% 97.94% 19.49% -246.20% - -251.50% -219.43%
Invested Capital Growth		 -6.89% -5.01% -12.50% -11.22% -10.35% -11.03% -17.68% 19.86% - 15.99% 21.77%
Revenue Q/Q Growth		 6.78% 0.00% 17.18% 4.37% -0.87% -13.97% 10.43% 16.11% - -1.83% 5.47%
EBITDA Q/Q Growth		 -26.47% 0.00% 103.87% 41.48% -32.51% -69.75% 181.90% -189.67% - -15.30% -261.29%
EBIT Q/Q Growth		 -89.99% 0.00% 10,723.87% 70.87% -41.30% -122.10% 385.87% -447.68% - -210.87% -868.87%
NOPAT Q/Q Growth		 91.01% 0.00% 1,162.15% 104.73% -64.45% -157.73% 328.26% -357.28% - -111.63% -595.67%
Net Income Q/Q Growth		 107.35% 0.00% 15,961.29% 93.30% -60.18% -177.16% 290.23% -300.53% - 44.14% -2,445.62%
EPS Q/Q Growth		 113.79% 0.00% 0.00% 91.67% -60.87% -177.78% 290.48% -300.00% - 42.86% -2,425.00%
Operating Cash Flow Q/Q Growth		 25.32% 0.00% -7.23% 50.24% -17.03% -31.09% 91.30% -205.35% - 234.95% -107.23%
Free Cash Flow Firm Q/Q Growth		 57.74% 0.00% 228.69% 5.59% -27.43% -21.41% 98.43% -229.20% - 35.65% -56.42%
Invested Capital Q/Q Growth		 -4.18% 0.00% -2.02% -1.07% -3.24% -5.14% -9.35% 44.05% - -11.67% -4.82%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.06% 88.65% 89.36% 89.99% 85.01% 89.48% 89.83% 90.13% - 88.74% 84.63%
EBITDA Margin		 14.24% 15.93% 27.72% 37.57% 25.58% 9.00% 22.96% -17.73% - 9.62% -14.72%
Operating Margin		 -0.61% -2.20% 13.41% 23.25% 12.29% -6.85% 7.34% -31.35% - -4.01% -26.46%
EBIT Margin		 0.60% 0.17% 15.63% 25.58% 15.15% -3.89% 10.07% -30.17% - -2.86% -26.32%
Profit (Net Income) Margin		 0.72% 0.09% 11.83% 21.91% 8.80% -7.89% 13.60% -23.49% - -1.10% -26.65%
Tax Burden Percent		 118.69% 51.03% 75.72% 85.66% 58.10% 202.83% 134.98% 77.85% - 38.54% 101.25%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Effective Tax Rate		 -18.69% 48.97% 24.28% 14.34% 41.90% 0.00% -34.98% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 -0.60% 0.00% 0.00% 0.00% 7.10% -5.05% 10.99% -20.92% - -3.38% -25.63%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1.94% 0.00% 0.00% 0.00% 6.17% -3.70% 9.50% -19.97% - -4.25% -21.65%
Return on Net Nonoperating Assets (RNNOA)		 0.38% 0.00% 0.00% 0.00% -1.97% 1.31% -3.87% 6.08% - 1.65% 9.24%
Return on Equity (ROE)		 -0.22% 0.00% 0.00% 0.00% 5.12% -3.74% 7.12% -14.83% - -1.73% -16.38%
Cash Return on Invested Capital (CROIC)		 6.79% 5.14% 13.33% 11.89% 20.17% 19.61% 27.79% -21.69% - -21.35% -34.85%
Operating Return on Assets (OROA)		 0.25% 0.00% 0.00% 0.00% 7.58% -1.96% 4.97% -14.89% - -1.56% -15.55%
Return on Assets (ROA)		 0.29% 0.00% 0.00% 0.00% 4.40% -3.98% 6.70% -11.59% - -0.60% -15.75%
Return on Common Equity (ROCE)		 -0.22% 0.00% 0.00% 0.00% 5.12% -3.74% 7.12% -14.83% - -1.73% -16.38%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 6.01% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.18 -1.61 17 35 12 -7.18 16 -42 -2.76 -5.83 -41
NOPAT Margin		 -0.72% -1.12% 10.15% 19.91% 7.14% -4.79% 9.90% -21.95% - -2.81% -18.52%
Net Nonoperating Expense Percent (NNEP)		 1.34% 0.75% 1.21% 1.31% 0.92% -1.34% 1.49% -0.94% - 0.87% -3.98%
Return On Investment Capital (ROIC_SIMPLE)		 -0.12% - - - 1.15% -0.68% 1.54% -3.97% -0.25% -0.54% -3.93%
Cost of Revenue to Revenue		 11.94% 11.35% 10.64% 10.01% 14.99% 10.52% 10.17% 9.87% - 11.26% 15.37%
SG&A Expenses to Revenue		 49.47% 60.23% 51.03% 39.70% 45.60% 60.03% 56.54% 93.53% - 60.26% 61.01%
R&D to Revenue		 14.21% 17.36% 15.56% 16.53% 16.45% 17.97% 13.37% 15.29% - 18.99% 13.45%
Operating Expenses to Revenue		 88.66% 90.84% 75.95% 66.74% 72.72% 96.32% 82.49% 121.48% - 92.75% 111.09%
Earnings before Interest and Taxes (EBIT)		 0.99 0.24 26 45 26 -5.83 17 -58 -1.91 -5.95 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 23 23 47 66 45 13 38 -34 24 20 -32
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.72 2.01 1.54 1.71 1.93 1.77 1.66 2.55 - 2.76 2.62
Price to Tangible Book Value (P/TBV)		 7.73 8.02 5.24 4.91 5.03 4.44 3.79 8.73 - 7.32 6.10
Price to Revenue (P/Rev)		 2.60 0.00 0.00 0.00 3.02 2.74 2.65 3.93 - 3.83 3.25
Price to Earnings (P/E)		 1,201.42 0.00 0.00 0.00 27.03 29.52 27.36 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.08% 0.00% 0.00% 0.00% 3.70% 3.39% 3.65% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.94 2.39 1.78 2.09 2.53 2.34 2.29 3.09 - 3.74 3.53
Enterprise Value to Revenue (EV/Rev)		 2.24 0.00 0.00 0.00 2.40 2.09 1.87 3.54 - 3.34 2.80
Enterprise Value to EBITDA (EV/EBITDA)		 15.05 0.00 0.00 0.00 8.83 8.17 7.67 38.89 - 54.55 0.00
Enterprise Value to EBIT (EV/EBIT)		 262.66 0.00 0.00 0.00 16.25 15.19 15.12 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 25.80 27.73 24.67 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.26 0.00 0.00 0.00 9.25 8.49 6.64 33.53 - 31.13 116.89
Enterprise Value to Free Cash Flow (EV/FCFF)		 27.53 45.38 12.46 16.56 11.85 11.22 7.46 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.06 0.06 0.05 0.05 0.05 0.03 0.00 0.01 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -0.19 -0.25 -0.25 -0.28 -0.32 -0.35 -0.41 -0.30 - -0.39 -0.43
Leverage Ratio		 1.65 1.68 1.39 1.37 1.35 1.35 1.33 1.34 - 1.35 1.34
Compound Leverage Factor		 1.65 1.68 1.39 1.37 1.35 1.35 1.33 1.34 - 1.35 1.34
Debt to Total Capital		 5.35% 5.24% 4.71% 4.42% 4.37% 2.83% 0.00% 1.06% - 0.00% 0.00%
Short-Term Debt to Total Capital		 5.35% 5.24% 4.71% 4.42% 4.37% 2.83% 0.00% 1.06% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 94.65% 94.76% 95.29% 95.58% 95.63% 97.17% 100.00% 98.94% - 100.00% 100.00%
Debt to EBITDA		 0.58 0.00 0.00 0.00 0.26 0.18 0.00 0.18 - 0.00 0.00
Net Debt to EBITDA		 -2.43 0.00 0.00 0.00 -2.26 -2.54 0.00 -4.36 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 -20.79 0.00 0.00 0.00 0.77 0.60 0.00 -0.43 - 0.00 0.00
Net Debt to NOPAT		 87.62 0.00 0.00 0.00 -6.59 -8.62 0.00 10.44 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 3.86 3.71 3.32 4.06 5.07 4.87 4.81 5.43 - 5.48 5.29
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.70 1.73 1.91 2.20 2.35 2.44 2.58 1.80 - 1.96 2.08
Quick Ratio		 1.38 1.42 1.62 1.88 2.04 2.16 2.32 1.37 - 1.51 1.68
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 51 34 111 117 85 67 133 -171 -157 -101 -158
Operating Cash Flow to CapEx		 0.00% 15,484.27% 55,662.50% 26,760.00% 20,847.89% 9,357.49% 12,864.84% -47,801.55% - 0.00% -846.83%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -68.44
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -2.08
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -2.32
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.41 0.00 0.00 0.00 0.50 0.50 0.49 0.49 - 0.55 0.59
Accounts Receivable Turnover		 3.92 0.00 0.00 0.00 4.62 4.55 4.54 4.30 - 4.74 4.71
Inventory Turnover		 0.99 0.00 0.00 0.00 1.18 1.24 1.36 1.08 - 1.20 1.55
Fixed Asset Turnover		 42.33 0.00 0.00 0.00 52.79 54.96 56.99 60.57 - 72.67 78.10
Accounts Payable Turnover		 0.95 0.00 0.00 0.00 1.00 0.95 0.95 0.84 - 0.92 1.06
Days Sales Outstanding (DSO)		 93.02 0.00 0.00 0.00 78.93 80.15 80.48 84.79 - 77.01 77.46
Days Inventory Outstanding (DIO)		 368.03 0.00 0.00 0.00 308.52 293.71 268.42 336.97 - 303.06 235.79
Days Payable Outstanding (DPO)		 383.20 0.00 0.00 0.00 365.26 385.22 383.68 433.41 - 395.54 343.13
Cash Conversion Cycle (CCC)		 77.85 0.00 0.00 0.00 22.19 -11.36 -34.78 -11.65 - -15.47 -29.88
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 702 671 658 651 629 597 541 780 784 693 659
Invested Capital Turnover		 0.83 0.00 0.00 0.00 0.99 1.05 1.11 0.95 - 1.20 1.38
Increase / (Decrease) in Invested Capital		 -52 -35 -94 -82 -73 -74 -116 129 155 95 118
Enterprise Value (EV)		 1,362 1,606 1,171 1,362 1,590 1,394 1,242 2,410 - 2,592 2,327
Market Capitalization		 1,581 1,864 1,471 1,718 1,997 1,828 1,765 2,680 - 2,976 2,699
Book Value per Share		 $16.87 $17.01 $17.42 $18.28 $18.76 $18.47 $19.00 $18.72 $18.52 $18.70 $17.77
Tangible Book Value per Share		 $3.75 $4.25 $5.11 $6.35 $7.19 $7.37 $8.32 $5.48 $6.41 $7.06 $7.62
Total Capital		 974 981 1,005 1,054 1,083 1,061 1,064 1,061 1,093 1,077 1,031
Total Debt		 52 51 47 47 47 30 0.00 11 31 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -219 -258 -300 -357 -406 -434 -523 -270 -278 -384 -372
Capital Expenditures (CapEx)		 -0.04 0.25 0.06 0.20 0.21 0.33 0.46 0.13 0.43 0.00 0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.11 -17 -18 -8.13 -13 -28 -70 -6.66 28 -27 4.05
Debt-free Net Working Capital (DFNWC)		 255 281 330 395 441 436 453 274 337 358 376
Net Working Capital (NWC)		 203 230 282 348 394 406 453 263 306 358 376
Net Nonoperating Expense (NNE)		 -2.36 -1.73 -2.83 -3.51 -2.89 4.65 -6.11 2.96 1.35 -3.54 18
Net Nonoperating Obligations (NNO)		 -219 -258 -300 -357 -406 -434 -523 -270 -278 -384 -372
Total Depreciation and Amortization (D&A)		 22 23 20 21 18 19 21 24 26 26 25
Debt-free, Cash-free Net Working Capital to Revenue		 0.02% 0.00% 0.00% 0.00% -1.90% -4.16% -10.54% -0.98% - -3.42% 0.49%
Debt-free Net Working Capital to Revenue		 41.97% 0.00% 0.00% 0.00% 66.64% 65.24% 68.03% 40.28% - 46.04% 45.29%
Net Working Capital to Revenue		 33.40% 0.00% 0.00% 0.00% 59.48% 60.75% 68.03% 38.63% - 46.04% 45.29%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.02 $0.00 $0.36 $0.70 $0.28 ($0.21) $0.40 ($0.80) ($0.07) ($0.04) ($1.01)
Adjusted Weighted Average Basic Shares Outstanding		 54.54M 54.80M 54.98M 55.15M 55.10M 55.86M 56.02M 56.55M 56.45M 57.65M 58.07M
Adjusted Diluted Earnings per Share		 $0.04 $0.00 $0.36 $0.69 $0.27 ($0.21) $0.40 ($0.80) ($0.07) ($0.04) ($1.01)
Adjusted Weighted Average Diluted Shares Outstanding		 55.51M 55.63M 55.72M 56.02M 55.96M 55.86M 56.64M 56.55M 56.45M 57.65M 58.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 54.97M 55.11M 55.22M 55.81M 55.99M 56.07M 57.34M 57.58M 58.04M 58.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.84 -2.17 14 34 13 -1.82 8.50 -42 9.68 -4.16 -2.13
Normalized NOPAT Margin		 -0.51% -1.51% 8.19% 19.42% 7.26% -1.21% 5.14% -21.95% - -2.00% -0.97%
Pre Tax Income Margin		 0.60% 0.17% 15.63% 25.58% 15.15% -3.89% 10.07% -30.17% - -2.86% -26.32%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -24.90
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -17.53
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -25.15
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -17.77
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Supernus Pharmaceuticals (NASDAQ: SUPN) showed a much stronger operating profile in Q1 2026 than it did a year ago, but the quarter still finished with a small net loss because expenses remained high relative to revenue. The company continues to generate solid cash from operations and maintains a strong liquidity position, though the balance sheet has shifted away from the huge cash/investment cushion it held in prior periods.

  • Revenue rebounded nicely year over year. Q1 2026 revenue rose to $207.7 million from $149.8 million in Q1 2025, a strong improvement of roughly 39%.
  • Gross profit remained very strong. Gross profit was $184.3 million, producing a gross margin of about 88.7%, which is excellent for a pharmaceutical company.
  • Operating cash flow was solid. The company generated $66.5 million in operating cash flow in Q1 2026, up from $30.6 million in Q1 2025.
  • Liquidity remains comfortable. Supernus ended Q1 2026 with $184.9 million in cash and equivalents plus $199.4 million in short-term investments.
  • Leverage looks minimal. Short-term debt was zero at the end of Q1 2026, which reduces near-term balance sheet risk.
  • Equity base remains substantial. Total equity stood at $1.08 billion, giving the company a sizable capital cushion.
  • Share count continues to rise modestly. Weighted average diluted shares increased to about 57.6 million from 56.5 million in Q1 2025, which can limit per-share earnings growth.
  • Investing activity is still centered on securities management. The company bought $78.4 million of investments and sold $59.2 million, suggesting excess cash is being actively managed rather than deployed into large capital projects.
  • Supernus remained unprofitable on a GAAP basis. Q1 2026 net loss was $2.3 million, or $(0.04) per share, versus a $11.8 million loss in Q1 2025.
  • Operating expenses still exceeded gross profit. SG&A, R&D, amortization, and special charges together totaled $192.6 million, pushing operating income to a loss of $8.3 million.

Looking at the last several years, the trend is mixed but improving. In early 2024 and early 2025, Supernus had multiple quarters of losses and volatile operating results. By mid-2025, profitability improved meaningfully, including a strong Q2 2025 quarter with $22.5 million in net income. However, Q3 and Q4 2025 swung back to losses, and Q1 2026 also posted a small loss. That tells investors the business can be profitable, but earnings are still somewhat uneven.

The balance sheet has also changed in an important way. At the end of Q1 2025, Supernus had a very large cash and investment position, but by Q1 2026 total current assets were $731.6 million versus current liabilities of $373.9 million, implying a still-healthy current ratio of about 2.0x. That is constructive, but the company is no longer sitting on the extraordinary liquidity position seen in earlier periods like Q1 2024, when short-term investments and cash were much larger.

Bottom line: Supernus appears financially stable with good liquidity and strong gross margins, but earnings consistency remains a concern. For retail investors, the key question is whether the company can turn its improved revenue base into sustained operating profit without relying too heavily on investment income or one-time items.

08/15/26 08:42 PM ETAI Generated. May Contain Errors.

Supernus Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Supernus Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Supernus Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$38.55 million in 2025, falling from $13.94 million in 2015. The previous period was $73.87 million in 2024. Find out what analysts predict for Supernus Pharmaceuticals in the coming months.

Supernus Pharmaceuticals' total operating income in 2025 was -$62.28 million, based on the following breakdown:
  • Total Gross Profit: $644.39 million
  • Total Operating Expenses: $706.67 million

Over the last 10 years, Supernus Pharmaceuticals' total revenue changed from $147.47 million in 2015 to $718.95 million in 2025, a change of 387.5%.

Supernus Pharmaceuticals' total liabilities were at $390.93 million at the end of 2025, a 17.6% increase from 2024, and a 288.5% increase since 2015.

In the past 10 years, Supernus Pharmaceuticals' cash and equivalents has ranged from $33.50 million in 2015 to $288.64 million in 2020, and is currently $128.45 million as of their latest financial filing in 2025.

Over the last 10 years, Supernus Pharmaceuticals' book value per share changed from 1.80 in 2015 to 18.52 in 2025, a change of 929.3%.


Related Companies

Financial statements for NASDAQ:SUPN last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel